Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Clinical trial NCT01082939 · COMPLETED
Trial details
- NCT number
- NCT01082939
- Sponsor
- M.D. Anderson Cancer Center
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2002-12-01
- Primary completion
- 2011-01-01
- Enrollment
- 80
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.